Standards; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
5-Bromo-N2,N4-dicyclopentylpyrimidine-2,4-diamine is an impurity of Palbociclib (P139900), an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.